Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Funding News June 11, 2007 NEWS & NOTICES FOR THE WEEK ENDING JUNE 8, 2007 NCRR/NIH Roadmap to Publish a Limited Solicitation for Pilot Projects in Informatics for Clinical and Translational Science Awards (CTSAs) [NOT-RR-07-012] (6/8) The overarching purpose of the CTSA program is to provide an institutional home for the evolving new discipline of clinical and translational science. The objective of the solicitation will be to advance development, adoption, implementation, and dissemination broadly of tools, standards, and practices for information exchange to facilitate the performance of research by clinical investigators and their collaborators within, among, and beyond CTSAs. The FOA will be published in the fall. The award will be in the form of a contract ranging from $500K to $1M a year over 2 years. Two awards are expected to be made. LCRC Annual Report Due Dr. Ochoa requests that members of the Cancer Center please provide the Grants and Development Office with the following lists: • Honors/recognitions, committee appointments, and new collaborations since January 1 (July 1, 2006, if you did not provide this information for the semi-annual report in December). • Peer-reviewed publications and invited presentations since January 1 (or July 1...). Please indicate which, if any, publications are co-authored by Tulane researchers. • Active grants/contracts. This information should include the agency name, award number, dates of award, annual direct and total costs, project title, and your role on the project (if not PI). This list should not include grants in no-cost extensions. If you would like information about LCRC funding opportunities, please contact us at 568-3494. Correct email Address for Dr. Tiskus When preparing applications, please use [email protected] as the contact address for Dr. Tiskus. New Grants and Development Office Jonna Ellis and I are now located in 409B of the CSRB building. My number is 568-3494; Jonna’s is x5144. NIH & CDC SOLICITATIONS NCI/NCAAM Omics and Variable Responses to CAM: Secondary Analysis of CAM Clinical Trials – R01, R21[PAR-07-377], [PAR-07-378] (6/6) Opens July 14 Receipt dates September 14, 2007-2009 Closes September 15, 2009 Intended to leverage NCCAM’s and NIH’s investment in ongoing and completed clinical trials, this initiative encourages examination of differences in genomics, proteomics, and metabolomics and other omics that may be responsible for variations in individual responses to complementary and alternative medicine (CAM) (NCCAM) or bioactive food component (NCI) interventions using samples obtained from ongoing and completed clinical studies. Restrictions Competitive renewals may not be awarded. NIH/OBSSR/NCCAM/NEI/NHLBI/NIAMS/NIAID/NICHD/NIDCR/NIDDK/NIEHS/NIGMS/NIMH/NINDS /NINR/NIA/NIAAA/NICHD/NIDA/NILM/OPHR/(CDC) Behavioral and Social Science Research on Understanding and Reducing Health Disparities – R01, R21 [PAR-07-379][PAR-07-380] (6/7) Opens July 19, 2007 LOI Due August 20, 2007-9 Receipt date September 19, 2007-8; September 18, 2009 Closes September 19, 2009 Encourages behavioral and social science research on the causes and solutions to health and disabilities disparities in the US population. Health disparities between, on the one hand, racial/ethnic populations, lower socioeconomic classes, and rural residents and, on the other hand, the overall US population are major public health concerns. Emphasis is placed on research in and among three broad areas of action: (1) Public policy, (2) health care, and (3) disease/disability prevention. Particular attention is given to reducing health gaps among groups. Proposals that utilize an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, and/or employ innovative methods such as system science or community-based participatory research are particularly encouraged. Commitment 20-30 R01 awards and 10-20 R21 awards in Year 1 NIGMS Research on Interventions that Promote Research Careers – R01 [RFA-GM-08-005] (6/5) Opens September 24, 2007 LOI Due September 24, 2007 Receipt date October 22, 2007 Closes October 23, 2007 Supports research to test assumptions regarding existing or potential interventions that are intended to increase the preparedness for careers in biomedical and behavioral research, with a particular interest in those interventions specifically designed to increase the number of underrepresented minority students entering careers in biomedical and behavioral research. The proposed research need not be restricted to underrepresented minority students. Â Comparative research which analyses the experience of all ethnicities in order to place that of underrepresented students in context and to learn whether and how interventions should be tailored to make more underrepresented students successful in biomedical careers may well be particularly illuminating and is, therefore, encouraged. Commitment $2.4M for 6-8 awards NIDCR Osteoimmunology- Crosstalk between Immune System and Bone – R01, R21 [RFA-DE-08-006], [RFA-DE-08-007] (6/7) Open Date: Receipt Date: Close Date: May 31, 2007 July 9, 2007 July 10, 2007 Solicits novel research projects designed to provide a fundamental understanding of the intersystem crosstalk between alveolar bone and the immune system, and how osteoimmunology operates in normal and pathologic conditions. It will contribute to our understanding of how both systems are physiologically regulated, at the molecular and cellular levels and at the level of organ systems. Specifically this initiative solicits research that will identify the influence of the immune system on oral bone biology; the extent to which normal immune responses affect oral bone homeostasis; the consequences of oral bone metabolism on adaptive immune responses; the interplay between the immune system and age-related oral bone changes; and the changes in the host immune system that impact oral bone loss. The emerging field of osteoimmunology is important for formulating intervention strategies for periodontitis as well as for basic and clinical studies in related fields. Examples of Knowledge Gaps • • • • • • • • • • The immunopathological mechanism(s) that link periodontal and dental pulp infection and pathological bone resorption. The role of innate and adaptive immune cells in normal and pathological bone turnover in the oral cavity. The role of cytokines and other cellular factors in oral bone development and pathology. The role of cells/factors that regulate B cells and how B cells regulate osteoblasts and osteoclasts in the oral cavity. The roles of circulating lymphocytes and other immune cells in normal and pathological oral bone metabolism. Identification of new therapeutic strategies to prevent inflammation-induced bone loss. Definition of regulatory signals and pathways that influence both oral bone and immune cells, such as signals between immune cells and neural cells. Immunomodulatory strategies to reduce or prevent oral bone loss. Whether osteo-immune cross-talk is different in oral vs axial/appendicular bone. Ontogeny of osteoimmune interactions in the host. Commitment $2M for R01s and $1M for R21s in FY08 NCI Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis – R01 [PA-07-021],[ PA-07-022] (11/20/06) Opens Receipt Dates Closes January 5, 2007 October 5, January 5, June 5 (standard R01) October 16, January 16, June 16 (standard R21) January 3, 2010 Encourages clinicians, epidemiologists, geneticists, statisticians, and translational researchers working in the field of cancer control and prevention to improve existing models for cancer risk and prognosis. Specifically, this program is designed to stimulate efforts towards: (1) the development of comprehensive models of risk, prognosis, and response to therapy, (2) integrating diverse types of data in these areas, (3) validating such models, and (4) evaluating the utility of integrated models in research and clinical settings. Restriction • Doesn’t fund research on developing/characterizing biomarkers NIH Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis – R21 [PA-06-299] (3/30/06) May 2, 2006 Opens October 16, January 16, June 16 (standard) Receipt Dates November 2, 2008 Closes Intended to support translational studies which identify promising new means for cancer detection and diagnosis and which provide the initial, critical information necessary to decide whether potential clinical utility justifies further investment. Applicants should explain the significance of the proposed research in terms of its potential for clinical application. Priority will be given to welldesigned studies that will help us to differentiate those new markers and techniques that have potential clinical utility from those that do not. This funding opportunity announcement is sponsored jointly by the Cancer Diagnosis Program and the Cancer Therapy Evaluation Program (Division of Cancer Diagnosis and Treatment) and the Cancer Biomarkers Research Group (Division of Cancer Prevention) of the National Cancer Institute. NCI Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations – R01 [PA-07-100] (12/1/06) January 5, 2007 Opens October 5, January 5, June 5 (standard) Receipt Dates Closes November 2, 2009 Solicits innovative research applications to enhance mechanistic understanding of the dynamic interrelationship between bioactive food components and/or food combinations and cancer prevention. Projects proposed in response to this FOA must focus on either multiple dietary bioactive components, intact foods, and/or multiple foods utilizing physiologically relevant concentrations of the bioactive agents. The objective is to investigate the impact of dietary components on complex cellular and molecular networks to better understand the basis for the multifaceted interactions of food components in cancer prevention. Proposed projects should apply new high-throughput genomic, epigenomic, proteomic, and metabolomic technologies to either evaluate multiple molecular targets within a cancer process or multiple processes. The main outcome of these studies must be the prioritization of targets/processes that are most relevant to cancer prevention by dietary components. The overall longterm goal is to use such information in developing dietary strategies to reduce cancer risk and/or modify tumor behavior. See also NCI Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components – R21 [PA-07-362], summarized in Funding News 15 Additional Opportunities • NIAID International Research in Infectious Diseases (IRID) Program – R01 [PAR-07-376] (6/8) PRIVATE GRANTS Parker B. Francis Fellowship in Pulmonary Research Receipt Date Starts October 1 July 1 Intended to provide assured support, during their earlier years, for junior members of the faculty as they establish their laboratories. It is hoped that the assurance provided through the Program will encourage successful applicants to be more venturesome in their research and future applications for support than would otherwise be likely. The ideal candidate is in transition between postdoctoral training and a career as an independent investigator. A broad array of approaches to lung biology and respiratory medicine, ranging from cell and molecular studies, to those involving epidemiologic and clinical aspects of human subjects are appropriate. We also encourage applications from pulmonary medicine specialists interested in pursuing research in bioethical aspects of pulmonary medicine or critical care. Potential topics include, but are not limited to, the ethics of clinical trials in critical care, end-of-life decisions and resource allocation. The context of all these topics should be pulmonary biology and lung disease. Solicitation Program press release Scientific Advisory Board Award Commitment Restrictions $48-50K/year for 3 years • No more than 7 years research experience • At least 2-3 co/publications (1-2 accepted on rare occasions) • Citizen/perm resident of N. American country—or can demonstrate the steps have been taken towards permanent residenty • • • • • • ≥75% effort towards research project No NIH K o r R01 grants Any NIH/MRC training grants must be relinquished at time of award Mentor required Only 2 active awards per department No indirect costs. Leukemia and Lymphoma Society Career Development Program Pre-app Receipt Date September 17,2008 October 1,2008 Supports fundamental research in genetics, molecular and cell biology, molecular pharmacology, molecular virology and immunology. The program also encompasses translational research directly relevant to the improved treatment or diagnosis of leukemia, lymphoma, myeloma and, where applicable, to prevention. CDP Reviewers List (January 8-10, 2007 review) Scholars $105K/year for 5 years (+5K indirects) • Indep faculty pos. or equiv. • Substantial funding record Additional Scholars in Clinical Research $105K/year for 5 years (+5K indirects) • Conducting applied resh. often involving early-phase clinical trials • Indep faculty pos. or equiv. • Concomitant support for rsh. Special Fellow $60.K/year for 3 years (+4.5K indirects) • ≥2 years postdoctoral experience • Sponsor Special Clinical Research Fellow $60.K/year for 3 years (+4.5K indirects) • MD/Phd or equiv. w/ 2 years clinical hematology, oncology, hematology/on cology, or hematopatholo gy training or postdoctoral research training in a clinical discipline (e.g., cytogenetics, molecular pathology) • Evidence that career focus will be on prevention, diagnosis, or treatment of leukemia, lymphoma, or myeloma Annual renewals on a non-competitive basis Fellow $51.7K/year for 5 years (+3.3K indirects) • ≤ 2 yrs postdoctoral exp. • Sponsor • Substantial funding record American Gastrological Association (AGA) Funderburg Research Scholar Award Receipt Date September 5 Awarded to an established investigator working on novel approaches in gastric cancer, including the fields of gastric mucosal regeneration and regulation of cell growth (not as they relate to peptic ulcer disease inflammation (including Helicobacter pylori) as precancerous lesions; genetics of gastric oncogenes in gastric epithelial malignancies; epidemiology of gastric cancer; etiology of malignancies; or clinical research in the diagnosis or treatment of gastric carcinoma. Award Commitment Requirements Application $25K/year for 2 years One (1) award per year • Must hold faculty positions at North American • Established researcher in gastrology • AGA member Via email American Gastrological Association (AGA) Research Scholar Awards Receipt Date Start Date September 5 July 1 Enables young investigators to develop independent and productive research careers in gasterentrology, heptology and related areas by ensuring that a major proportion of their time is protected for research. Recipients will be selected based on novelty, feasibility, and significance of the proposal; attributes of the candidate, including potential for independence; evidence of institutional commitment; and the research environment. Candidate should state clearly how the additional training will benefit his/her research career. Criteria.pdf Application.doc Award Commitment Restrictions Review Application $75K a year for 3 years Six (6) awards • Ph, MD or equiv • Within 5 years of postdoc/clinical training • Members of AGA • Full-time faculty appointment at North American university • Cannot hold/have held an R01, R29, R21, K award, VA Career Development Award, or nonfederal award with similar objectives ( American Liver Foundation, Crohn’s and Colitis Foundation of America, Robert Wood Johnson Foundation or Glaxo Institute of Digestive Health). • Must devote 70% research effort to gastrointestinal tract or liver. • If an extraumural award of equal or greater amount is received during period of this award, 75% must be relinquished. If another award is received prior to this award, one must be relinquished. • If applicant has project incorporated into a senior investigator’s federal grant, that project must be cleary delineated from the proposed research. Review committee of AGA members Via email American Gastrological Association (AGA) Bridging Grants June 14, October, 14, February 14 Receipt Dates: Assists investigators were not awarded their first R01 or the first renewal of their R01 to continue their gastroenterology related research. Two awards will be made following each of the three annual NIH review cycles and availability of Summary Statements. Award Commitment Restrictions $50K for 1 year 6 awards per year • For investigators applying for their first R01 or second R01 either as a competitive renewal or a new R01 (includes investigators going from a K award to their first R01). • Cannot receive over $75K in extramural funding • MD, PhD or equiv • Faculty appointment at university/research institution • NIH proposal must have been approved and not funded or have received high commendation but was not funded. American Cancer Society (ACS) Various Programs Receipt Date October 15 The following programs are summarized in Funding News 3S: • • • • • • • ACS Mentored Research Scholar Grant in Applied and Clinical Research (April 1, too) Cancer Control Career Development Awards for Primary Care Physicians Postdoctoral Fellowships (April 1, too) Doctoral Training Grants in Oncology Social Work Master's Training Grants in Clinical Oncology Social Work Physician Training Awards in Preventive Medicine Doctoral Degree Scholarships in Cancer Nursing The ACS Mentored Research Scholar Grant in Applied and Clinical Research is summarized in Funding News 2S. (Applications also accepted April 1.) APPROACHING DEADLINES The following programs have been summarized in previous issues of Funding News, which are available on the Cancer Center website under Research/Grants/Summary Information. (Red indicates that an LOI or preapplication was required prior to the application date.) Due Date Program More Info Issue # June 12 DOD BCRP Idea Award W81XWH-07BCRP-IDEA 11 June 12 DOD BCRP Impact Award W81XWH-07BCRP-IMPT 11 June 12 NIH NHLBI Career Transition Award – K23 PAR-07-317 June 16 Standard R03 and R21 applications due June 16 Thrasher Research Fund (clinical/translational pediatric research) June 19 NHLBI Short-Term Research Education Program to Increase 15 RFA-HL-07-013 12 – LOI Diversity in Health-Related Research – R25 June 20 NCI/NEI/NHLBI/NHGRI/NIA/NIAAA/NIAMS/NIBIB/NICHD/NIC CR/NIDA/NIEHS/NIGMS/NIMH/NINDS/NINR Nanoscience and Nonotechnology in Biology and Medicine – R01, R21 PAR-07-033 PAR-07-034 2 June 25 NIH NIAID HIV Interdisciplinary Network for Pathogenesis Research in Women – U19 RFA-AI-07-009 8 June 25 NIAID HIV Interdisciplinary Network for Pathogenesis Research in Women – U19 RFA-AI-07-009 7 June 26 NIAID Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP) – U19 RFA-AI-07-019 10 June 26 AACR Funding Opportunity for Metastatic Colon Cancer Research 15 June 27 AACR Jeannik M. Littlefield- Grants in Metastatic Colon Cancer Research 18 June 28 NIH Roadmap National Institutes of Health Rapid Access to Interventional Development (NIH-RAID Pilot) – X01 PAR-07-358 14 June 29 NIAID B Cell Immunology for Protective HIV-1 Vaccines – U01, R21 RFA-AI-07-014 RFA-AI-07-015 10 June 29 NIH NIEHS/NHGRI Human Genes and the Environment Research Training Program/NRSA Institutional Training Grants – T32 RFA-ES-07-002 5 July 2 American Institute for Cancer Research (AICR) Investigator Initiated Grant (IIG) and Post-Doctoral Grant Award (PDA) July 10 NCRR National Gene Vector Biorepository and Coordinating Center – P40 RFA-RR-07-002 10 July 9 Quick Trial Grants For Novel Cancer Therapies: Exploratory Research – R21 PAR-06-45 1 July 12 Ellison Medical Foundation (EMF) Senior Scholar Award in Aging July 12 NSF Biomolecular Systems Cluster, Cellular Systems Cluster, and Genes and Genome Systems Cluster PD 04-1144 PD 04-1114 PD 04-1112 1 July 13 – LOI FIC/NCI/NIAAA/NIAID/NIDCR/NIDA/NINH/NINR/ORWH AIDS International Training and Research Program – D43 PAR-07-239 12 July 14 – LOI NIDCR Oral Mucosal Vaccination against HIV Infection – R01, R21 RFA-DE-08-003 RFA-DE-08-004 12 July 17 Competitive Continuation of Centers of Biomedical Research Excellence (COBRE) – P20 RFA-RR-07-001 11 14 2 July 19 NHLBI Short-Term Research Education Program to Increase Diversity in Health-Related Research – R25 RFA-HL-07-013 12 July 20 NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) PAR-07-345 11 July 23 Cancer Treatment Research Foundation July 29 – LOI NIH NIGMS Molecular Probes for Microscopy of Cells – R01 August 1 Melanoma Research Foundation – Established Investigator Award; Career Development Award August 3 NIH NCCAM Ruth L. Kirshstein NSRA for Postdoctoral Training in Complementary and Alternative Medicine – F32 PAR-07-319 6 August 4 – LOI NIHM National Neuro AIDS Tissue Consortium (NNTC) Data Coordinating Center (DCC) -– U01 RFA-MH-08-020 17 August 14 FIC/NCI/NIAAA/NIAID/NIDCR/NIDA/NINH/NINR/ORWH AIDS International Training and Research Program – D43 PAR-07-239 12 August 14 NIDCR Oral Mucosal Vaccination against HIV Infection – R01, R21 RFA-DE-08-003 RFA-DE-08-004 12 August 14 – LOI NIH Roadmap National Institutes of Health Rapid Access to Interventional Development (NIH-RAID Pilot) – X01 PAR-07-358 14 August 15 Burroughs Wellcome Fund (BWF) Clinical Scientists Awards in Basic Research August 20 NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) PAR-07-345 11 August 21 – LOI Specialized Programs of Research Excellence (SPOREs) in Human Cancer, 2007 – P50 PAR-06-505 1 August 21– LOI NIH FIC/NCI/NIA/NIBIB/NIEHS/NINDS/ODS Global Research Initiative Program, Basic/Biomedical Sciences – R01 PAR-07-239 10 August 25 Avon Foundation – Breast Cancer Prevention Research Initiative August 27 – LOI NIH NCI Application of Emerging Technologies for Cancer Research – R21, R33, SBIR(R43,R44), STTR(R41,42) RFA-CA-07-035 RFA-CA-07-036 RFA-CA-07-041 RFA-CA-07-042 3 August 27 – LOI NIH NCI Innovations In Cancer Sample Preparation – SBIR(R43,R44), STTR(R41,42) RFA-CA-07-043 RFA-CA-07-044 3 August 27 – LOI NIH NCI Innovative Technologies for Molecular Analysis of Cancer (IMAT) – R21, R33, SBIR(R43,R44), STTR(R41,42) RFA-CA-07-033 RFA-CA-07-034 RFA-CA-07-039 RFA-CA-07-040 3, 16 August 29 NIH NIGMS Molecular Probes for Microscopy of Cells – R01 PAR-07-234 9 16 PAR-07-234 9 17 12 17 Sept TBA Concern Foundation Conquer Cancer Now Award 18 Sept. 4 American Lung Association – Research Grants, Clinical Research Grants, Career Investigators; Training Awards, and Alliance Awards 17 Sept. 4 NIHM National NeuroADIS Tissue Consortium (NNTC) Data Coordinating Center (DCC) – U01 RFA-MH-08-020 17 Sept. 7 NCI/NBIB/NEI/NHLBI/NHGRI/NIA/NIAMS/NICHD/NIDA/NIDCD/ NIDCR/NIEHS/NINDS Bioengineering Research Partnerships – R01 PAR-07-352 12 Sept. 7 Standard AIDS-related applications due, including: • NIDA AIDS-Science Track Award for Research Transition (ASTART) – R03 PAR-07-347 12 Sept. 14 Cancer Research and Prevention Foundation (CRPF) Grants and Fellowship Program Sept. 14 NIH Roadmap National Institutes of Health Rapid Access to Interventional Development (NIH-RAID Pilot) – X01 Sept. 15 Cancer Research and Prevention Foundation CRPF Grants and Fellowships Program Sept. 20 NIH Framework Programs for Global Health - R25 RFA-TW-08-001 15 Sept. 20 NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) PAR-07-345 11 Sept. 21 NIH FIC/NCI/NIA/NIBIB/NIEHS/NINDS/ODS Global Research Initiative Program, Basic/Biomedical Sciences – R01 PAR-07-239 10 Sept. 21 FIC/NCCAM/NIA/NIAAA/NIBIB/NIDCD/NIDCR/NIDA/NIEHS/NIN DS International Research Collaboration – Basic Biomedical (FIRCA-BB) – R03 PAR-07-335 10 Sept. 25 NIH NCI Cancer Education and Career Development Program – R25 PAR-06-511 3 Sept. 27 NIH NCI Application of Emerging Technologies for Cancer Research – R21, R33 RFA-CA-07-035 RFA-CA-07-036 3 Sept. 27 NIH NCI Innovative Technologies for Molecular Analysis of Cancer (IMAT) – R21, R33, SBIR(R43,R44), STTR(R41,42) RFA-CA-07-033 RFA-CA-07-034 3, 16 Sept. 28 NIH NCI Innovative Technologies for Molecular Analysis of Cancer (IMAT) –SBIR(R43,R44), STTR(R41,42) RFA-CA-07-039 RFA-CA-07-040 3, 16 Sept. 28 NIH NCI Application of Emerging Technologies for Cancer Research –SBIR(R43,R44), STTR(R41,42) RFA-CA-07-041 RFA-CA-07-042 3 Sept. 28 NIH NCI Innovations In Cancer Sample Preparation – SBIR(R43,R44), STTR(R41,42) RFA-CA-07-043 RFA-CA-07-044 3 Sept. 28 – LOI NHLBI Summer Institute Program to Increase Diversity in HealthRelated Research (SIPID) – R25 RFA-HL-07-012 17 12 PAR-07-358 14 4 Oct. 1 Charlotte Geyer Foundation 13 Oct. 1 Wendy Will Case Cancer Fund 14 Oct. 1 Burroughs Wellcome Fund – Biomedical Scientists 18 Oct. 1 NCI Clinical Correlative Studies: Exploratory Studies in Cancer Detection, Diagnosis and Prognosis – R21 Oct. 5 Standard R01 applications due Oct. 8 Cancer Treatment Research Foundation Oct. 12 Standard Career Development (K) applications due, including: • NHLBI/NIDDK/NIAAA/NIEHS Career Enhancement Award for Stem Cell Research – K18 • NIH Pathway to Independence (PI) Award (K99/R00) PA-05-165 15 16 PAR-07-358 PA-07-297 14 18 Oct. 15 American Cancer Society (ACS) • Cancer Control Career Development Awards for Primary Care Physicians • Postdoctoral Fellowships • Doctoral Training Grants in Oncology Social Work • Master's Training Grants in Clinical Oncology Social Work • Physician Training Awards in Preventive Medicine • Doctoral Degree Scholarships in Cancer Nursing 3S Oct. 15 ACS Mentored Research Scholar Grant in Applied and Clinical Research 2S Oct. 15 NCI-Avon “Progress for Patients” (PFP) Awards for Early Phase Clinical Interventions and Biomarkers in Breast Cancer (Limited Competitive Supplements [Revisions] for P30 Cancer Center Support Grants) PAR-07-244 10 Oct. 15 – LOI Oct. 16 NIH Centers for Research to Reduce Disparities in Oral Health – U54 (Cooperative Agreement) Standard R03, R21, R33, R34, and R36 applications due RFA-DE-08-008 15 Oct. 19 – LOI Thrasher Research Fund (clinical/translational pediatric research) Oct. 20 NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) PAR-07-345 11 Oct. 23 NIGMS/NIEHS Collaborative Studies on Systems Biology of Complex Phenotypes – R01 PAR-07-358 14 Oct. 29 NHLBI Summer Institute Program to Increase Diversity in HealthRelated Research (SIPID) – R25 RFA-HL-07-012 17 Nov. 15 NCI-Avon “Progress for Patients” (PFP) Awards for Early Phase Clinical Interventions and Biomarkers in Breast Cancer (Limited Competitive Supplements [Revisions] for P30 Cancer Center Support Grants) PAR-07-244 10 Nov. 15 NIH Centers for Research to Reduce Disparities in Oral Health – U54 (Cooperative Agreement) NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) RFA-DE-08-008 15 PAR-07-345 11 Nov. 19 15 Nov. 20 Thrasher Research Fund (clinical/translational pediatric research) (LOI due June 16) 15 Dec. 1 – LOI Gerber Foundation Grants 15 Dec. 5 Kimmel Foundation Translational Science Award 2S Dec.8 NIH NCCAM Ruth L. Kirshstein NSRA for Postdoctoral Training in Complementary and Alternative Medicine – F32 Dec. 14 American Institute for Cancer Research (AICR) Investigator Initiated Grant (IIG) and Post-Doctoral Grant Award (PDA) Dec. 15 NIH Roadmap National Institutes of Health Rapid Access to Interventional Development (NIH-RAID Pilot) – X01 PAR-07-358 14 Dec. 20 NIDA/NIEHS Mechanism for Time-Sensitive Research Opportunities – R21 (LOI due 1 month prior) PAR-07-345 11 PAR-07-319 6 14 GENERAL INFORMATION○ Unless otherwise specified, for each program description summarized in Funding News, the following guidelines apply: • • • • • • • • • • • Dollar amounts represent direct costs. NIH R01 awards are for unspecified amounts that are dependant on available funding and the nature of applications received; they are renewable. NIH R03 awards are up to of $200K over two years and are nonrenewable. NIH R21 awards are up to $275K over two years and are nonrenewable. NIH AIDS-related proposals are associated with the standard receipt dates May 7, September 7 and January 7. Applicants/Institutions can submit more than one application. All applicants with the skills, knowledge and resources necessary to perform proposed research are eligible. No institutional restrictions other than the general NIH standards apply. Not every NIH Institute and Centers supports all types of funding mechanisms. For example, when co-sponsoring an initiative, NEIHS may offer both R01 and R03 award mechanisms, whereas NIE will offer only the former. For programs with multiple participating Institutes, the sponsoring Institute is underlined. In the table of Approaching Deadlines, dates in red indicate that a preapplication or LOI was due. No. 19, June 4, 2007 Jonna Ellis & Heidi Davis, Editor Office of Grants and Development [email protected]